secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-295456
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics extends headquarters lease to Dec 2026; aggregate rent ~$5.05M
--------------------------------------------------------------------------------

- Entered first amendment to lease for corporate HQ and lab at 45-47 Wiggins Ave, Bedford, MA.
- Lease term extended by two years to December 31, 2026.
- Aggregate estimated base rent over extension period approximately $5.05 million.
- Option to further extend for five years at 95% of then-prevailing market rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523295456/0001193125-23-295456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523295456/d523640d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-295456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer